What Bioferon Treats: Main Uses and Benefits

The therapeutic application of Bioferon (Interferon Alfa-2b) is primarily focused on supporting the management of specific malignant diseases and persistent viral infections. Its use is considered relevant across several major clinical domains where additional symptomatic support is needed.

This medicine plays a role in managing conditions characterized by systemic imbalance and heightened physiological activity, including Chronic Hepatitis B and C, certain hematological malignancies (like leukemias), and solid tumors (such as high-risk Malignant Melanoma). It is also relevant for easing challenging manifestations like the hormone-driven symptoms associated with Carcinoid Syndrome.

The use is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

“The focus is on supporting the management of the underlying condition activity, which contributes to improved patient comfort during symptomatic periods.”

Quick Fact: Support for Carcinoid Syndrome Symptoms

This therapy assists with maintaining functional stability when severe, systemic symptoms, such as flushing and diarrhea, become more noticeable and interfere with daily functioning.

The official regulatory profile for Bioferon (Interferon Alfa-2b) strictly defines patient eligibility by outlining specific absolute contraindications and conditional use populations.

Populations for whom use is Contraindicated

The medicine must not be used in individuals with certain severe, unstable health conditions, as mandated by regulatory documents. These contraindications include a history of severe psychiatric disorders (such as severe depression or suicidal ideation), severe pre-existing cardiovascular disease, and active autoimmune disease (including autoimmune hepatitis).

It is also prohibited for patients with decompensated cirrhosis of the liver (Child-Pugh B or C), End Stage Renal Disease (GFR < 15 mL/min), or a known hypersensitivity to the product.

Age and Conditional Use Eligibility

Use is established for adults in approved indications. For pediatric patients, use is generally limited to children ge 3 years of age for Chronic Hepatitis C, and use is not established for other indications. Older adults may require closer monitoring and dose consideration. Regarding reproductive health, use is not recommended during pregnancy due to potential fetal risk, and females of reproductive potential must use effective contraception. Breastfeeding should be avoided during therapy.

Bioferon Interactions with other medicines and products

Interacting Product Categories and Substances

The primary area of interaction concern for Bioferon (interferon beta-1b) relates to substances that have the potential to affect liver function. Co-administration with known hepatotoxic drugs or other substances, such as alcohol, may increase the risk of liver injury.

No formal, dedicated drug interaction studies have been conducted. However, the interferon class of medicines may potentially reduce the activity of certain cytochrome P450 enzymes, which are crucial for metabolizing many other medications. This suggests a potential for altered metabolism of co-administered drugs that rely on these pathways.

Interaction Restrictions and Monitoring

• Hepatotoxic Agents: The potential risk of using Bioferon in combination with any drug known to cause liver damage (hepatotoxicity), or products like alcohol, must be carefully considered before use or when adding a new agent to the patient's regimen.
• Alcohol: Avoid or limit the consumption of alcohol while on this medication due to the potential for increased risk of hepatic injury.
• Monitoring: Patients receiving Bioferon, especially when co-administered with other potentially hepatotoxic agents, should be closely monitored for signs and symptoms of liver injury, and regular liver function tests are advised.
• Symptom Management: Concurrent use of analgesics and/or antipyretics (such as acetaminophen or ibuprofen) is permitted on treatment days to help manage common flu-like symptoms.

Bioferon, containing iron dextran, is administered and rapidly dissociates, leading to the mobilization of its iron component. The iron is specifically targeted and bound by transferrin, the primary iron-transport protein in the plasma. The iron-transferrin complex is subsequently internalized by erythroid precursor cells in the bone marrow via interaction with the transferrin receptor 1 (TfR1) on the cell surface. This cellular uptake provides iron for the intracellular synthesis of heme, a critical prosthetic group required for the formation of hemoglobin molecules. The availability of iron, a crucial substrate, directly modulates the rate of the heme biosynthesis pathway within these cells. The resultant increase in available hemoglobin facilitates the system-level physiological consequence of enhanced oxygen-carrying capacity of the circulating erythrocytes.

Administration Guidelines for Bioferon (Interferon Beta)

Bioferon, a form of interferon beta, is administered based on specific clinical requirements. The preparation and frequency of use depend on the specific formulation of interferon beta prescribed.

Administration Scope

Required Procedures

All patients must receive proper training from a healthcare professional before self-administering the medication. The first injection should be performed under professional supervision.

• Titration: Treatment is typically initiated with a titration schedule where the dose is gradually increased over several weeks (e.g., 4 to 6 weeks) to the full recommended dose. This process is intended to improve tolerance at the start of therapy.
• Preparation: If the product is supplied as a lyophilized powder, it must be reconstituted with the supplied diluent. The vial should be gently swirled to dissolve; vigorous shaking must be avoided. The resulting solution must be visually inspected for discoloration or particulate matter before use.
• Procedural Rule: Injection sites must be rotated with each dose to minimize the risk of severe injection site reactions. The injection should not be administered into irritated, bruised, or infected skin areas.
• Missed Dose (Subcutaneous): If a dose is missed, it should be administered as soon as possible, but not on two consecutive days. The patient should then resume the regular schedule.

These guidelines describe the necessary procedural steps for use, ensuring the drug is administered at the correct dose, route, and frequency.

Bioferon: Recent Clinical Evidence

Clinical research involving products identified as Bioferon primarily relates to the study of recombinant human Interferon beta-1a (a biosimilar formulation) and, in some contexts, Interferon-alpha compounds.

Evidence in Multiple Sclerosis

Studies focused on the biosimilar Interferon beta-1a formulation of Bioferon have investigated its comparative characteristics against approved reference products. These investigations aim to confirm the similarity in the molecule’s biological and physicochemical properties. Phase I pharmacokinetic studies in healthy subjects have been conducted to assess the absorption and disposition profile of the biosimilar formulation following intravenous and subcutaneous administration.

The broader class of Interferon beta-1a medications, for which the Bioferon biosimilar is intended, has been the subject of extensive randomized controlled trials (RCTs) for relapsing forms of Multiple Sclerosis (MS). Findings from this body of evidence generally indicate a reduction in the frequency of clinical relapses and a slower accumulation of physical disability in adult patients with relapsing MS, compared to placebo. A decrease in the appearance of new or enlarging brain lesions, as detected by MRI scans, has also been observed in some of these trials.

Evidence in Chronic Hepatitis C

Other research, primarily comparative effectiveness studies, has examined products labeled as Bioferon (Interferon-alpha) for the management of Chronic Hepatitis C infection. When evaluated as part of a combination therapy, findings from certain international trials suggest that this formulation of Interferon-alpha was associated with an End-of-Treatment Response (ETR) and Sustained Virological Response (SVR) within the range observed for other conventional interferon therapies. Long-term safety and effectiveness data for biosimilar antiviral treatments, including those named Bioferon, remain a focus of ongoing research efforts.

Key Studies & References

1. Review of the Clinical Evidence for Interferon Beta 1a (Rebif) in the Treatment of Multiple Sclerosis

Common questions about Bioferon (FAQ)

Q: What is the main reason Bioferon is prescribed?

A: Official product information states that the medicine is used to treat conditions that include specific forms of cancer and chronic viral infections. The full list of conditions for which the medicine is approved is detailed in the official regulatory labeling.

Q: Are there any specific foods or drinks that should be avoided while taking Bioferon?

A: Official product information typically notes that alcohol consumption should be limited or avoided during treatment. The regulatory documents do not usually list specific foods that must be avoided alongside the injectable forms of the medication.

Q: Can Bioferon be used by elderly patients?

A: Regulatory guidelines note that use in older adults is possible. However, caution is advised because elderly patients may be more sensitive to side effects like dizziness or mood changes. Closer monitoring or dose adjustments may be needed due to potential age-related changes in organ function.

Q: What does the research evidence say about Bioferon's long-term use?

A: Studies have examined the long-term use of interferons for specific conditions. Ongoing research and extension studies are used to evaluate the medicine's safety and effectiveness profiles over extended periods.

Q: Do studies suggest Bioferon is useful for other conditions besides the main one?

A: While the product is officially approved for a defined set of conditions, some regulatory summaries may reference the drug’s use for other specific conditions under certain criteria (compendial uses). Examples include certain types of lymphomas or Kaposi's sarcoma.

Q: Is Bioferon considered a long-term treatment or a short-course medicine?

A: The length of time a person uses Bioferon is highly dependent on the condition being treated. Treatment may involve a short course lasting only a few weeks, or it may be continued for multiple years, particularly for chronic conditions.

Q: Is it normal for the color of the Bioferon tablet to vary slightly?

A: Official guidance for the injectable forms states that the prepared solution should be clear and may range from colorless to light yellow. Official guidance requires patients to visually inspect the liquid before administration. The product should be discarded if it appears cloudy, discolored, or contains particles.

Q: Where can I find the official FDA/EMA patient information leaflet for Bioferon?

A: The official patient information, such as the Medication Guide or Patient Information Leaflet, is available through government-run public databases. These resources, including the FDA's DailyMed or the EMA's product pages, contain the complete, authoritative information reviewed by regulatory agencies.

Q: If I have a mild reaction, what steps are usually recommended in official sources?

A: Official guidance focuses on clinical management if adverse reactions become severe. This may involve temporarily withholding the medicine or making a dose adjustment until reactions subside. Permanent discontinuation is considered only if the intolerance is severe and persistent.

Q: Are there any lifestyle changes recommended alongside taking Bioferon?

A: Patient guidance included in regulatory documents suggests several general precautions. These include maintaining good oral hygiene, taking steps to prevent infections, and staying well hydrated throughout the course of therapy.

Q: What is the most serious interaction listed for Bioferon?

A: Regulatory sources highlight interactions with drugs that may increase the risk of severe side effects, such as a drop in white blood cells (neutropenia). Specific drug combinations may also be entirely contraindicated.

Q: Why do some people experience initial nausea with Bioferon?

A: Official documents classify nausea as a very common adverse reaction, confirming its high frequency during treatment. This side effect is a known part of the medicine's safety profile.

Q: Is Bioferon a drug that is often stopped abruptly, or should it be tapered off?

A: Official guidance states that the medicine's use is managed by temporarily withholding the dose or reducing the dose based on toxicity criteria. While the medicine itself is not typically tapered, other drugs used in combination with it may require a gradual reduction.

Q: Can I drive or operate machinery while taking Bioferon?

A: Official warnings note that this medicine can cause side effects such as dizziness, sleepiness, or hallucinations. If these effects occur, patients should not drive or operate heavy machinery.

Q: Why does Bioferon have a black box warning, if it does?

A: Regulatory labeling includes this warning because these medicines may cause or aggravate life-threatening disorders. These serious conditions include neuropsychiatric events, autoimmune diseases, and ischemic events.

Q: Does Bioferon affect birth control pills?

A: Regulatory guidelines note the requirement for using two forms of effective birth control during treatment and for six months afterward, especially in combination with certain other drugs. This precaution applies to both female patients and the female partners of male patients.

Q: Is Bioferon known to cause weight changes?

A: Yes, weight loss is documented in the official regulatory safety profile as a common adverse reaction. Decreased weight is listed among the possible side effects associated with the medicine.

Q: What steps are outlined for discontinuing Bioferon?

A: Official documents outline criteria for discontinuing use, which are based on the development of certain severe toxicities. These criteria include specific blood count or liver enzyme abnormalities that do not improve after attempts at dose reduction or temporary withholding.

Q: Are there any known cross-allergies with Bioferon?

A: Regulatory guidance advises patients to disclose any allergies they have to the medicine itself or to other medications within the same pharmacological class, such as other Interferon alfa products. This is part of the standard pre-treatment screening process.

Q: Does Bioferon need to be taken with food or on an empty stomach?

A: Official regulatory documentation for the injectable form does not typically contain explicit instructions requiring the medicine to be taken with food or on an empty stomach. The administration guidance focuses on the injection procedure itself.

Official Storage and Disposal Requirements

Storage Conditions

To maintain the identity, strength, quality, and purity of Bioferon, the product must be kept in the refrigerator, stored between 2 C to 8 C (36 F to 46 F). It is essential to keep the product in its original outer carton to protect it from light. The medication must not be frozen or shaken.

Handling and Stability

Any unused portion remaining in a single-dose vial or syringe must be discarded after the specified in-use period has passed. Always store the medication securely, out of the reach of children.

Disposal Rules

Used needles, syringes, or auto-injectors (sharps) must be disposed of immediately in an FDA-cleared sharps disposal container. Unused non-sharp medication should be returned to a drug take-back location or disposed of by mixing it with an unappealing substance, placing it in a sealed bag, and discarding it in the household trash, in accordance with local regulations. Do not flush the medication down the toilet.